T-cell prolymphocytic leukemia

Expert Review of Anticancer Therapy

Volumn 9, Issue 3, 2009, Pages 365-371

  Khot, Amit ^a   Dearden, Claire ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Clinical features; Pathogenesis; T cell prolymphocytic leukemia; Treatment

Indexed keywords

ALEMTUZUMAB; CD2 ANTIGEN; CD3 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; ONCOPROTEIN; PENTOSTATIN; PREDNISOLONE; PROTEIN KINASE B; PROTEIN MTCP1; PROTEIN TCL1A; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; UNCLASSIFIED DRUG; VINCRISTINE;

B CELL LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER INFILTRATION; CD4 CD8 RATIO; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ELECTRON MICROSCOPY; GENE DELETION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; LYMPHADENOPATHY; MORPHOLOGY; OVERALL SURVIVAL; PATHOGENESIS; PROLYMPHOCYTIC LEUKEMIA; REVIEW; SEX DIFFERENCE; SURVIVAL TIME; T CELL LEUKEMIA; T LYMPHOCYTE; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIAGNOSIS, DIFFERENTIAL; DRUG ADMINISTRATION SCHEDULE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, PROLYMPHOCYTIC, T-CELL; PROGNOSIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 65749084050     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.9.3.365     Document Type: Review

References (46)

1. Galton DAG, Goldman JM, Wiltshaw E et al. Prolymphocytic leukaemia. Br. J. Haematol. 27, 7-23 (1974).
2. Catovsky D, Galetto J, Okas A et al. Prolymphocytic leukemia of B and T cell type. Lancet 2, 232-234 (1973).
3. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues (4th Edition). International Agency for Research on Cancer, Lyon, France (2008).
4. Bommhardt U, Beyer M, Hunig T, Reichardt HM. Molecular and cellular mechanisms of T cell development. Cell. Mol. Life Sci. 61, 263-280 (2004).
5. Pawson R, Schulz TF, Matutes E et al. The human T-cell lymphotropic viruses type 1/11 are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia. Leukaemia 11, 1305-1311 (1997).
6. Virgilio L, Narducci MG, Isobe M et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc. Natl Acad. Sci. USA 91, 12530-12534 (1994).
7. Lan K, Murakami M, Choudhuri T et al. Detection of Epstein-Barr virus in T-cell prolymphocytic leukemia cells in vitro. J. Clin. Virol. 43(3), 260-265 (2008).
8. Herling M, Patek KA, Teitell MA et al. High TCL1 expression and intact T-cell receptor signalling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood 111, 328-337 (2008).
9. Madani A, Choukroun V, Soulier J et al. Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) translocations. Blood 87, 1923-1927 (1996).
10. Laine J, Kunstle G, Obata T et al. The proto-oncogene TCL1 is an Akt kinase coactivator. Mol. Cell 6, 395-407 (2000).
11. Brito-Babapulle V, Catovsky D. Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia. Cancer Genet. Cytogenet. 55, 1-9 (1991).
12. Xu Y, Ashley T, Brainerd E et al. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects and thymic lymphoma. Genes Dev. 10, 2411-2422 (1996).
13. Taylor AM, Metcalfe JA, Thick M et al. Leukaemia and lymphoma in ataxia telangiectasia. Blood 87, 423-438 (1996).
14. Stilgenbauer S, Schaffner C, Litterst A et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat. Med. 3, 1155-1159 (1997).
15. Stoppa-Lyonnet D, Soulier J, Lauge A et al. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood 91, 3920-3926 (1998).
16. Yuille MA, Coignet LJ. The ataxia telangiectasia gene in familial and sporadic cancer. Recent Results Cancer Res. 154, 156-173 (1998).
17. Yamaguchi M, Yamamoto K, Miki T et al. T-cell prolymphocytic leukemia with der(11)t(1;11)(q21;q23) and ATM deficiency. Cancer Genet. Cytogenet. 146, 22-26 (2003).
18. Matutes E, Brito-Babapulle V, Swansbury J et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 78, 3269-3274 (1991).
19. Garand R, Goasguen J, Brizard A et al. Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Francais d'Haematologie Cellularie. Br. J. Haematol. 103, 488-494 (1998).
20. Matutes E, Talavera GJ, O'Brien M et al. The morphological spectrum of T-prolymphocytic leukemia. Br. J. Haematol. 64, 111-124 (1986).
21. Ginaldi L, De Martinis M, Matutes E et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res. 22, 185-191 (1998).
22. Sugimoto T, Imoto S, Matsuo Y et al. T-cell receptor -ζ T-cell leukemia with the morphology of T-cell prolymphocytic leukemia and a postthymic immunophenotype. Ann. Hematol. 80, 749-751 (2001).
23. Malajei SH, Brito-Babapulle V, Hirons LR et al. Abnormalities of chromosomes 8, 11, 14 and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization. Cancer Genet. Cytogenet. 103, 110-116 (1998).
24. Kojima K, Kobayashi H, Imoto S et al. 14q11 abnormality and trisomy 8q are not common in Japanese T-cell prolymphocytic leukemia. Int. J. Hematol. 68, 291-296 (1998).
25. Soulier J, Pierron G, Vecchione D et al. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer 31, 248-254 (2001).
26. Durig J, Bug S, Klein-Hitpass L et al. Combined single nucleotide polymorphismbased genomic mapping and global gene expression profiling identifies novel chromosomal imbalances, mechanisms and candidate genes important in the pathogenesis of T-cell prolymphocytic leukaemia with inv (14)(q11q32). Leukaemia 21(10), 2153-2163 (2007).
27. Delgado J, Bustos JG, Jimenez MC et al. Are activation markers (CD25, CD38 and CD103) predictive of sensitivity to purine analogues in patients with T-cell prolymphocytic leukemia and other lymphoproliferative disorders? Leuk. Lymphoma 43, 2331-2334 (2002).
28. Mercieca J, Matutes E, Dearden C et al. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J. Clin. Oncol. 12, 2588-2593 (1994).
29. Pawson R, Dyer MJ, Barge R et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J. Clin. Oncol. 15, 2667-2672 (1997).
30. Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with Campath-1H. Blood 98, 1721-1726 (2001).
31. Keating MJ, Cazin B, Coutre S et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J. Clin. Oncol. 20, 205-213 (2002).
32. Dearden C, Matutes E, Cazin B et al. Very high response rates in previously untreated T-cell prolymphocytic leukemia patients receiving alemtuzumab (Campath-1H) therapy. Blood 102 (2003) (Abstract 2378).
33. Khot A, Matutes E, Dearden C et al. Alemtuzumab administered by subcutaneous route is less effective than intravenous route for first line therapy of T-cell prolymphocytic leukaemia: results of a pilot study (UKCLL05). Blood (ASH Annual Meeting Abstracts) 112 (2008) (Abstract 4204).
34. Hopfinger G, Kandler G, Koller E et al. T-PLL 1 protocol of the German CLL Study Group (GCLLSG) - a prospective Phase 2 trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FCM) followed by alemtuzumab consolidation as first line treatment in T-PLL. Blood (ASH Annual Meeting Abstracts), 110 (2007) (Abstract 2130).
35. Ravandi-Kashani F, Kantarjian H, Faderl S et al. Combination therapy with alemtuzumab and pentostatin is effective and has acceptable toxicity in patients with T-lymphoid neoplasms. Blood (ASH Annual Meeting Abstracts) (2006) (Abstract 4971).
36. Krishnan B, Cazin B, Ireland R et al. Improved survival for patients with T-cell prolymphocytic leuk receiving alemtuzumab therapy followed by stem cell transplantation. Leuk. Lymphoma 48 (Suppl. 1), 6-13 (2007).
37. Garderet L, Bittencourt H, Kaliski A et al. Treatment of T-prolymphocytic leukaemia with non-myeloablative allogeneic stem cell transplantation. Eur. J. Haematol. 66, 137-139 (2001).
38. De Lavallade H, Faucher C Furst S et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukaemia: graft-versus-tumor effect and long-term remission. Bone Marrow Transplant. 37, 709-710 (2006).
39. Ozpuyan F, Meyer P, Ni H, Al-Masri H, Alkan S. Bortezomib induces apoptosis in T-cell prolymphocytic leukemia (T-PLL). Leuk. Lymphoma 48(11), 2247-2250 (2007).
40. Satou Y, Matsuoka M. Proteasome inhibitor, bortezomib (Vercade), potently inhibits the growth of adult T-cell leukemia cells. Nippon Rinsho 62(7), 1363-1367 (2004).
41. Roeth A, de Beer D, Duerig J et al. Extremely short telomeres and high telomerase activity in T-cell prolymphocytic leukemia (T-PLL): an optimal target for telomerase inhibition with GRN163L? J. Clin. Oncol. 26(Suppl.) (2007) (Abstract 7061).
42. Ishitsuka K, Yotsumoto F, Katsuya H et al. A promising therapeutic implication of a novel Bcl-2 family inhibitor ABT-737 for adult T-cell leukemia/lymphoma. Blood (ASH Annual Meeting Abstracts) 112 (2008) (Abstract 1584).
43. Yamamoto K, Tobinai K, Utsunomiya A et al. Phase I study of KW-0761, a defucosylated anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma (ATL) or peripheral T-cell lymphoma (PTCL): updated results. Blood (ASH Annual Meeting Abstracts) 112 (2008) (Abstract 1007).
44. Maeda Y, Yamaguchi T, Hirase C et al. Clinical efficacy of ATRA for adult T-cell leukemia. Blood (ASH Annual Meeting Abstracts), 112 (2008) (Abstract 4985).
45. Horwitz S, Duvic M, Kim Y et al. Pralatrexate (PDX) is active in cutaneous T-cell lymphoma: Preliminary results of a multi-center dose-finding trial. Blood (ASH Annual Meeting Abstracts), 112 (2008) (Abstract 1569).
46. Zhao Y, Xu Y, Lan J et al. Anti-proliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition. Blood (ASH Annual Meeting Abstracts), 110 (2007) (Abstract 4285).